Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

Clinical and Experimental Metastasis

Volumn 30, Issue 5, 2013, Pages 631-642

  Bayraktar, S ^a   Gutierrez Barrera, A M ^a   Lin, H ^a   Elsayegh, N ^a   Tasbas, T ^a   Litton, J K ^a   Ibrahim, N K ^a   Morrow, P K ^a   Green, M ^a   Valero, V ^a   Booser, D J ^a   Hortobagyi, G N ^a   Arun, B K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BRCA mutation; Chemotherapy; Metastatic breast cancer; Recurrence; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; HORMONE; IXABEPILONE; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; FAMILY HISTORY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROBABILITY; PROTEIN EXPRESSION; TIME OF DEATH;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84878585448     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9567-8     Document Type: Article

References (57)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF et al (2002) SEER cancer statistics review, 1975-2002. http://seer.cancer.gov/csr/1975-2002/. Accessed 26 Jan 2013
2. O'Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20-29
3. Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20-37
4. Giordano SH, Buzdar AU, Kau SWC, Hortobagyi GN (2002) Improvement in breast cancer survival: results from M.D. Anderson Cancer Center protocols from 1975-2000. 2002 ASCO Annual Meeting. Proc Am Soc Clin Oncol 21:2002 (abstr 212)
5. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
6. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874
7. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418-8423
8. Smid M, Wang Y, Zhang Y et al (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114
9. Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638-2645
10. Gao D, Du J, Cong L et al (2009) Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I-III of operable patients. Jpn J Clin Oncol 39(2):97-104
11. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52(1):108-118
12. Kennedy RD, Quinn J, Johnston PH, Harkin DP (2002) BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360:1007-1014
13. Verhoog LC, Brekelmans CT, Seynaeve C et al (1999) Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17:3396-3402
14. Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):115-123
15. Brekelmans CT, Tilanus-Linhorst MM, Seynaeve C et al (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, B. Eur J Cancer 43:867-876
16. Kriege M, Seynaeve C, Meijers-Heijboer H et al (2008) Distant disease-free interval, site of first relapse and post-relapse survival in BRCA carriers. Breast Cancer Res Treat 111:303-311
17. Bonadona V, Dussart-Moser S, Voirin N et al (2007) Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat 101(2):233-245
18. Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119(1):13-24
19. Tan DS, Rothermundt C, Thomas K et al (2008) "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26(34):5530-5536
20. Yang D, Khan S, Sun Y et al (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306(14):1557-1565
21. Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654-2663
22. Singletary SE, Greene FL (2003) Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 21(1):53-59
23. Black MM, Speer FD (1957) Nuclear structure in cancer tissues. Surg Gynecol Obstet 105(1):97-102
24. Bayraktar S, Gutieerz-Barrera A, Liu DD et al (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treatment 130(1):145-153
25. Bayraktar S, Gutierrez-Barrera AM, Liu D et al (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-153
26. Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90(15):1138-1145
27. Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282-4288
28. Byrski T, Gronwald J, Huzarski T et al (2008) Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 108(2):289-296
29. Arun B, Bayraktar S, Liu DD et al (2011) Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 29(28):3739-3746
30. Zakhartseva LM, Gorovenko NG, Podolskaya SV et al (2009) Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations. Exp Oncol 31(3):174-178
31. Hall MJ, Reid JE, Burbidge LA et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115(10):2222-2233
32. Haffty BG, Silber A, Matloff E et al (2006) Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet 43(2):133-137
33. John EM, Miron A, Gong G et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298(24):2869-2876
34. Hunter KW, Broman KW, Voyer TL et al (2001) Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 61(24):8866-8872
35. Lifsted T, Le Voyer T, Williams M et al (1998) Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77(4):640-644
36. Park YG, Zhao X, Lesueur F et al (2005) Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 37(10):1055-1062
37. Crawford NP, Qian X, Ziogas A et al (2007) Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet 3(11):e214
38. Crawford NP, Alsarraj J, Lukes L et al (2008) Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci USA 105(17):6380-6385
39. Crawford NP, Walker RC, Lukes L et al (2008) The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis 25(4):357-369
40. Hsieh SM, Look MP, Sieuwerts AM et al (2009) Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res 11(5):R75
41. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429-4434
42. Foulkes WD, Metcalfe K, Hanna W et al (2003) Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98(8):1569-1577
43. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-1281
44. Rodriguez-Pinilla SM, Sarrio D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12(5):1533-1539
45. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
46. Lai R, Dang CT, Malkin MG et al (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101(4):810-816
47. Wang Y, Klijn JG, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671-679
48. Smid M, Wang Y, Klijn JG et al (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24(15):2261-2267
49. Albiges L, Andre F, Balleyguier C et al (2005) Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol 16(11):1846-1847
50. Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359(26):2814-2823
51. Kennedy RD, Quinn JE, Mullan PB et al (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96(22):1659-1668
52. Foulkes WD (2006) BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 5(2):135-142
53. James CR, Quinn JE, Mullan PB et al (2007) (2007) BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 12(2):142-150
54. Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6(1):R8-R17
55. Kriege M, Seynaeve C, Meijers-Heijboer H et al (2009) Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(23):3764-3771
56. Kurebayashi J, Yamamoto Y, Kurosumi M et al (2006) Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res 26(1B):695-701
57. Wysocki PJ, Korski K, Lamperska K et al (2008) Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit 14(7):SC7-SC10